NRF2 activation in BON‑1 neuroendocrine cancer cells reduces the cytotoxic effects of a novel Ruthenium(II)‑curcumin compound: A pilot study
Open Access
- 4 January 2024
- journal article
- research article
- Published by Spandidos Publications in Oncology Reports
- Vol. 51 (2) , 1-11
Abstract
Gastroenteropancreatic neuroendocrine neoplasms (GEP‑NEN) are a group of rare tumors whose specific pathogenetic mechanisms of resistance to therapies have not been completely revealed yet. Chemotherapy is the main therapeutic approach in patients with GEP‑NEN, however, novel combination regimens and targeted therapy are continuously explored. In the present study, the anticancer effect of a novel Ruthenium (Ru)(II)‑Bisdemethoxycurcumin (Ru‑bdcurc) compound was evaluated in BON‑1 cell line, one of the few cell lines derived from GEP‑NEN, largely used in experimental research of this type of tumors. The experimental data revealed that the Ru‑bdcurc compound induced cell death in a dose‑dependent manner, in vitro. Biochemical studies demonstrated that, in response to the lower dose of treatment, BON‑1 cells activated the nuclear factor erythroid 2‑related factor 2 (NRF2) pathway with induction of some of its targets including catalase and p62 as well as of the antiapoptotic marker Bcl2, all acting as chemoresistance mechanisms. NRF2 induction associated also with increased expression of endogenous p53 which is reported to be dysfunctional in BON‑1 cells and to inhibit apoptosis. Genetic or pharmacologic targeting of NRF2 inhibited the activation of the NRF2 pathway, as well as of endogenous dysfunctional p53, in response to the lower dose of Ru‑bdcurc, increasing the cell death. To assess the interplay between NRF2 and dysfunctional p53, genetic targeting of p53 showed reduced activation of the NRF2 pathway in response to the lower dose of Ru‑bdcurc, increasing the cell death. These findings identified for the first time a possible dysfunctional p53/NRF2 interplay in BON‑1 cell line that can be a novel key determinant in cell resistance to cytotoxic agents to be evaluated also in GEP‑NEN.Keywords
This publication has 65 references indexed in Scilit:
- NRF2 and STAT3: friends or foes in carcinogenesis?Discover Oncology, 2023
- Overview of the 2022 WHO Classification of Neuroendocrine NeoplasmsEndocrine Pathology, 2022
- NOXA‐mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin‐treated human acute myeloid leukemia cellsJournal of Cellular Physiology, 2021
- Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compoundsEuropean Journal of Cancer, 2021
- NRF2 and the Hallmarks of CancerCancer Cell, 2018
- p62 in Cancer: Signaling Adaptor Beyond AutophagyCell, 2016
- Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2Free Radical Biology and Medicine, 2015
- Mutant p53 in Cancer: New Functions and Therapeutic OpportunitiesCancer Cell, 2014
- Arene–RuII Complexes of Curcumin Exert Antitumor Activity via Proteasome Inhibition and Apoptosis InductionChemMedChem, 2012
- Blinded by the Light: The Growing Complexity of p53Cell, 2009